Table of Content

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview
4.1. Introduction
4.2. Hemoglobinopathies Market, by Region

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing prevalence of common rare blood-related diseases
5.1.1.2. Rising numbers of patients seeking hemoglobinopathies treatments
5.1.1.3. Increasing approvals from the regulatory bodies for novel hemoglobinopathies therapies
5.1.2. Restraints
5.1.2.1. High cost associated with hemoglobinopathies treatment
5.1.3. Opportunities
5.1.3.1. Ongoing R&D activities for the hemoglobinopathies treatment
5.1.3.2. Availability of new medicinal therapies and diagnostic methods for hemoglobinopathies treatment
5.1.4. Challenges
5.1.4.1. Lack of awareness about hemoglobinopathies therapies
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Bargaining Power of Customers
5.5.4. Bargaining Power of Suppliers
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework

6. Hemoglobinopathies Market, by Indication
6.1. Introduction
6.2. Sickle Cell Disease
6.3. Thalassemia
6.4.1. Alpha Thalassemia
6.4.2. Beta thalassemia

7. Hemoglobinopathies Market, by Treatment
7.1. Introduction
7.2. Blood Transfusion
7.3. Bone Marrow & Stem Cell Transplant
7.4. Chemotherapy
7.5. Curative Therapy
7.6. Gene Therapy
7.7. Hydroxyurea
7.8. Iron Chelation Therapy

8. Hemoglobinopathies Market, by Diagnosis
8.1. Introduction
8.2. Genetic Testing
8.3. Haemoglobin Isoelectric Focusing (Hb IEF)
8.4. Haemoglobin Solubility Test
8.5. Hemoglobin by High Performance Liquid Chromatography
8.6. Hemoglobin electrophoresis (Hb ELP)
8.7. Routine Red Blood Cell (RBC) Count

9. Hemoglobinopathies Market, by End-User
9.1. Introduction
9.2. Clinics
9.3. Diagnostic Laboratories
9.4. Hospitals

10. Americas Hemoglobinopathies Market
10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Hemoglobinopathies Market
11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Hemoglobinopathies Market
12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape
13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio
14.1. Key Company Profiles
14.1.1. Abbott Laboratories
14.1.2. Alnylam Pharmaceuticals, Inc.
14.1.3. Bio-Rad Laboratories Inc.
14.1.4. Biogen Inc.
14.1.5. Bluebird Bio, Inc.
14.1.6. Bristol Myers Squibb
14.1.7. CRISPR Therapeutics AG
14.1.8. Danaher Corporation
14.1.9. Emmaus Life Sciences Inc.
14.1.10. Gamida Cell Ltd.
14.1.11. Genetix Biotech Asia Pvt. Ltd
14.1.12. Laboratory Corporation
14.1.13. Medunik USA Inc.
14.1.14. Merck & Co. Inc.
14.1.15. Nexcelom Bioscience LLC
14.1.16. Novartis AG
14.1.17. PerkinElmer Inc.
14.1.18. Pfizer, Inc.
14.1.19. Prolong Pharmaceuticals, LLC
14.1.20. Regenacy Pharmaceuticals, Inc.
14.1.21. Sangamo Therapeutics, Inc.
14.1.22. Sanofi S.A.
14.1.23. Sebia
14.1.24. Shenzhen Mindray Bio-Medical Electronics Co., Ltd
14.1.25. Sysmex Corporation
14.1.26. Vertex Pharmaceuticals Incorporated
14.2. Key Product Portfolio

15. Appendix
15.1. Discussion Guide
15.2. License & Pricing



List of Figures

FIGURE 1. HEMOGLOBINOPATHIES MARKET RESEARCH PROCESS
FIGURE 2. HEMOGLOBINOPATHIES MARKET SIZE, 2023 VS 2030
FIGURE 3. HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. HEMOGLOBINOPATHIES MARKET DYNAMICS
FIGURE 7. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 8. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
FIGURE 10. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2030 (%)
FIGURE 12. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 14. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 18. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 23. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023
FIGURE 24. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023

List of Tables

TABLE 1. HEMOGLOBINOPATHIES MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018–2023
TABLE 3. HEMOGLOBINOPATHIES MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL HEMOGLOBINOPATHIES MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 6. HEMOGLOBINOPATHIES MARKET SIZE, BY SICKLE CELL DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 8. HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 9. HEMOGLOBINOPATHIES MARKET SIZE, BY ALPHA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. HEMOGLOBINOPATHIES MARKET SIZE, BY BETA THALASSEMIA, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 12. HEMOGLOBINOPATHIES MARKET SIZE, BY BLOOD TRANSFUSION, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. HEMOGLOBINOPATHIES MARKET SIZE, BY BONE MARROW & STEM CELL TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. HEMOGLOBINOPATHIES MARKET SIZE, BY CHEMOTHERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. HEMOGLOBINOPATHIES MARKET SIZE, BY CURATIVE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. HEMOGLOBINOPATHIES MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. HEMOGLOBINOPATHIES MARKET SIZE, BY HYDROXYUREA, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. HEMOGLOBINOPATHIES MARKET SIZE, BY IRON CHELATION THERAPY, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 20. HEMOGLOBINOPATHIES MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN ISOELECTRIC FOCUSING (HB IEF), BY REGION, 2018-2030 (USD MILLION)
TABLE 22. HEMOGLOBINOPATHIES MARKET SIZE, BY HAEMOGLOBIN SOLUBILITY TEST, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. HEMOGLOBINOPATHIES MARKET SIZE, BY HEMOGLOBIN ELECTROPHORESIS (HB ELP), BY REGION, 2018-2030 (USD MILLION)
TABLE 25. HEMOGLOBINOPATHIES MARKET SIZE, BY ROUTINE RED BLOOD CELL (RBC) COUNT, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 27. HEMOGLOBINOPATHIES MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. HEMOGLOBINOPATHIES MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 31. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 32. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 33. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 34. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 35. AMERICAS HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 36. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 37. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 38. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 39. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 40. ARGENTINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 41. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 42. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 43. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 44. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 45. BRAZIL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 46. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 47. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 48. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 49. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 50. CANADA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 51. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 52. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 53. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 55. MEXICO HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 57. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 58. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 59. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 60. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 61. UNITED STATES HEMOGLOBINOPATHIES MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 63. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 64. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 65. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 66. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 67. ASIA-PACIFIC HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 68. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 69. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 70. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 71. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 72. AUSTRALIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 73. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 75. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 76. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 77. CHINA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 78. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 79. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 80. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 81. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 82. INDIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 83. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 84. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 85. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 86. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 87. INDONESIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 89. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 90. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 91. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 92. JAPAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 93. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 95. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 96. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 97. MALAYSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 98. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 99. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 100. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 101. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 102. PHILIPPINES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 103. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 104. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 105. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 106. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 107. SINGAPORE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 108. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 109. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 110. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 111. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 112. SOUTH KOREA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 114. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 115. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 117. TAIWAN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 118. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 119. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 120. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 121. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 122. THAILAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 123. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 125. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 126. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 127. VIETNAM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 129. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 130. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 131. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 132. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 133. EUROPE, MIDDLE EAST & AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 134. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 135. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 136. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 137. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 138. DENMARK HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 139. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 140. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 141. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 142. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 143. EGYPT HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 144. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 145. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 146. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 147. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 148. FINLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 150. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 151. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 153. FRANCE HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 154. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 155. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 156. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 157. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 158. GERMANY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 159. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 161. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 162. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 163. ISRAEL HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 164. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 165. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 166. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 167. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 168. ITALY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 169. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 170. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 171. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 172. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 173. NETHERLANDS HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 175. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 176. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 178. NIGERIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 179. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 180. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 181. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 182. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 183. NORWAY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 184. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 186. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 187. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. POLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 189. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 190. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 191. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 192. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 193. QATAR HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 194. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 195. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 196. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 197. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 198. RUSSIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 200. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 201. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 202. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 203. SAUDI ARABIA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 206. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 208. SOUTH AFRICA HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 209. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 210. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 211. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 212. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 213. SPAIN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 214. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 216. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 217. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 218. SWEDEN HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 219. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 220. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 221. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 222. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 223. SWITZERLAND HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 224. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 225. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 226. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 227. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 228. TURKEY HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 230. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 231. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 232. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 233. UNITED ARAB EMIRATES HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 235. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY THALASSEMIA, 2018-2030 (USD MILLION)
TABLE 236. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 237. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 238. UNITED KINGDOM HEMOGLOBINOPATHIES MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 239. HEMOGLOBINOPATHIES MARKET, FPNV POSITIONING MATRIX, 2023
TABLE 240. HEMOGLOBINOPATHIES MARKET SHARE, BY KEY PLAYER, 2023
TABLE 241. HEMOGLOBINOPATHIES MARKET LICENSE & PRICING